Usman Baber to Prosthesis Design
This is a "connection" page, showing publications Usman Baber has written about Prosthesis Design.
Connection Strength
1.681
-
Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More. JACC Cardiovasc Interv. 2022 06 13; 15(11):1164-1166.
Score: 0.197
-
Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
Score: 0.161
-
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative. JACC Cardiovasc Interv. 2018 01 08; 11(1):53-65.
Score: 0.145
-
Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
Score: 0.140
-
Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
Score: 0.132
-
Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):28-38.
Score: 0.127
-
One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovasc Drugs Ther. 2021 04; 35(2):309-320.
Score: 0.045
-
One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
Score: 0.043
-
1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovasc Revasc Med. 2020 12; 21(12):1542-1547.
Score: 0.043
-
Comparison of One-Year Outcomes in Patients >75 Versus =75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). Am J Cardiol. 2020 07 15; 127:1-8.
Score: 0.043
-
1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. JACC Cardiovasc Interv. 2020 04 13; 13(7):820-830.
Score: 0.042
-
Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheter Cardiovasc Interv. 2021 04 01; 97(5):797-804.
Score: 0.042
-
1-year results after PCI with the COMBO stent in all-comers in Asia versus Europe: Geographical insights from the COMBO collaboration. Int J Cardiol. 2020 05 15; 307:17-23.
Score: 0.042
-
Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC Cardiovasc Interv. 2019 12 23; 12(24):2528-2537.
Score: 0.042
-
Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):558-564.
Score: 0.041
-
Stent Expansion and Endothelial Shear Stress in Bifurcation Lesions. Circ Cardiovasc Interv. 2019 06; 12(6):e007911.
Score: 0.040
-
Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. Int J Cardiol. 2019 07 15; 287:59-61.
Score: 0.039
-
Safety and Efficacy of Polymer-Free Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 02; 12(2):e007311.
Score: 0.039
-
Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.
Score: 0.039
-
Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis. Circ Cardiovasc Interv. 2018 10; 11(10):e006832.
Score: 0.038
-
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
Score: 0.035
-
Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newer-generation DES: Findings from a large multiethnic registry. Catheter Cardiovasc Interv. 2018 04 01; 91(5):859-866.
Score: 0.035
-
Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2016 10 24; 9(20):2124-2133.
Score: 0.033
-
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
Score: 0.033
-
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
Score: 0.032
-
Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan; 9(1):e002995.
Score: 0.032